Beta2-mimetic and Central Nervous System (BETACTIV)

Grenoble Alpes University Hospital Center (CHU)

Status: Completed

Conditions: Adrenergic Beta-2 Agonist Effect; Albuterol Effect

Treatments: Drug: Salbutamol; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT02925130

38RC14339

Details and patient eligibility

About

Beta2-mimetics such as Salbutamol have been shown to have ergogenic effects. Acute and chronic inhaled or oral doses of Salbutamol have been shown to increase whole body exercise and muscle performances. The underlying mechanisms are however unclear. Some data suggest that Salbutamol may have some effects on the central nervous system which may explain the improved exercise and neuromuscular performances. The present study aims to assess the effects of acite inhaled or oral Salbutamol intake on the neuromuscular system by using neurostimulation techniques and magnetic resonance imaging.

Full description

The effects of Salbutamol intake will be assessed by using transcranial magnetic stimulation on one hand and magnetic resonance imaging on the other hand. Maximal voluntary activation and cerebral activation will be measured during motor tasks performed until exhaustion after acute inhaled slabutamol intake, acture oral salbutamol intake or oral placebo intake.

Enrollment: 15 patients

Sex: Male

Ages: 18 to 35 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy subjects without respiratory and cordiovascular diseases
• Male
• Age between 18 and 35
• Trained subjects (>6 hours of physical activity per week)
• Non- or ex-smoker (smoking cessation since at least 1 year)

Exclusion criteria

• Respiratory, cardiovascular and metabolic diseases
• Neuromuscular diseases
• thyrotoxicosis, or diabetes treated with insulin
• alcoholism
• MRI contraindication
• TMS contraindication

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

15 participants in 3 patient groups, including a placebo group

Inhaled Salbutamol

Experimental group

Description:

Acute inhalation of 800 microgram Salbutamol

Treatment:

Drug: Salbutamol

Oral Salbutamol

Experimental group

Description:

Acute oral intake of 4 mg Salbutamol

Treatment:

Drug: Salbutamol

Placebo

Placebo Comparator group

Description:

Acute oral intake of a placebo

Treatment:

Drug: Placebo